STAT+: ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
Category: Medicine
STAT+: At ASCO, pharma leaders explain how ‘smart bomb’ drugs became useful against more cancers
CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today…
STAT+: ASCO 2024: FDA oncology head wants clinical trials to range beyond China alone
CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers…
STAT+: With expectations rising, Corbus reveals new data on its ADC bladder cancer treatment
CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor…
How can hospitals boost cancer screening rates? Researchers report that an AI helped
CHICAGO — People can be mightily reluctant to get a colonoscopy for reasons like cost,…
Opinion: Readers respond to essays on young caregivers, digital health, and more
To encourage robust, good-faith discussion about issues raised in First Opinion, STAT publishes selected Letters…
STAT+: HHS: Change Healthcare can make data breach notifications in lieu of hospitals
Change Healthcare can notify patients whose sensitive health information has been exposed as a result…
What to watch for in the crucial FDA meeting on MDMA therapy for PTSD
In less than three months, the Food and Drug Administration will decide whether to approve…
Woman is back on dialysis after doctors remove transplanted pig kidney
WASHINGTON — A woman who received a pig kidney transplant is back on dialysis just 47…
FDA approves Moderna’s RSV vaccine, its second licensed product
The Food and Drug Administration on Friday approved Moderna’s vaccine to protect older adults against…
STAT+: Pharmalittle: We’re reading about docs paid for endorsements, Novartis suing Maryland, and lots more
And so, another working week will soon draw to a close. Not a moment too…
The surprising outperformance of a new drug against existing competitors, and other biotech updates
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Ionis drug prevents swelling attacks caused by rare genetic disease in late-stage trials
Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on…
Drug treatment that insists on abstinence? Federal agencies are just saying no
For as long as the federal government has worked to support substance use treatment, it…
Opinion: The Pandemic Treaty will succeed only with investment to build strong health systems
As the 77th World Health Assembly takes place this week, negotiations around the Pandemic Treaty…
Opinion: Mothers in treatment for opioid use disorder shouldn’t also have to fight child protective services
Pregnant people and new mothers who are being treated for opioid addiction often have to…
NIH documents show how $1.6 billion long Covid initiative has failed so far to meet its goals
More than three years ago, the National Institutes of Health launched a $1 billion-plus initiative…
STAT+: Novartis sues Maryland over the role of contract pharmacies in a U.S. drug discount program
Novartis has filed a lawsuit seeking to block a Maryland law that requires the company…
STAT+: Ultragenyx gene therapy for rare liver ailment succeeds in late-stage trial
Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease…
Listen: An ASCO preview & another Duchenne trial failure
Which presentations are worth catching at ASCO this weekend? What is exon-skipping? And how do…
A third U.S. farm worker infected with bird flu is the first to experience respiratory symptoms
A third human case of H5 bird flu tied to the ongoing U.S. outbreak in…
STAT+: Many docs who tweeted product endorsements also took money from manufacturers, analysis shows
Most physicians who endorsed a prescription drug or medical device on X — formerly known…
STAT+: Did Sarepta Therapeutics earn $4 billion from exon-skipping drugs that don’t work?
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
Biohaven’s autoimmune drug disappoints, and other biotech news updates from the week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a deal for a Moderna bird flu shot, NIH trial shortcomings, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
Opinion: Stigma and the return of syphilis
Syphilis, one of the oldest infections known to humans, has returned to the U.S. at…
What the rescheduling of marijuana might — and might not — mean for scientific research
WASHINGTON — After years of inertia, the field of research into the health effects of…
STAT+: Value-based payment is getting renewed attention. What it means isn’t getting any clearer
WASHINGTON — Nearly 20 years ago, policymakers had an epiphany: The health care system should…
STAT+: Clinical lab trade group sues FDA over plan to regulate lab-developed tests
A group representing clinical labs across the country sued the Food and Drug Administration on…
STAT+: Akili, maker of a video game to treat ADHD, acquired for $34 million
A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video…
STAT+: Scientists install ‘window’ in the skull to record brain activity using ultrasound
Researchers may have a new way to watch the human brain pulse, thanks to an…
NIH-funded clinical trials often miss racial, gender diversity enrollment goals, report finds
WASHINGTON — Clinical trials that the National Institutes of Health funds often enroll fewer Black…
The new menstruation: Girls are getting their periods earlier and less regularly
Menstruation is a critical indicator of health. Whether and when someone with a uterus gets…
Opinion: Listen: What happens when kids become caregivers?
When it comes to childhood and young adulthood, most people in the U.S. think of…
STAT+: Pharmalittle: We’re reading about a Merck deal, weight loss drugs, and lots more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Biohaven protein-degrader drug falls short of investor expectations in early-study test
Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a…
Wegovy linked to lower risk of alcohol use disorder in real-world study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Reports: Looking to expand its pipeline, Merck to buy eye-disease startup EyeBio
LONDON — Merck is buying ophthalmology-focused startup EyeBio in a deal worth up to $3…
STAT+: Health insurers boast to investors about using AI, but they’d rather not talk about it
Health insurers are telling shareholders that they are ramping up the use of artificial intelligence…
New obesity drugs are seemingly everywhere. Black Americans feel left out
STAT teamed up with Word In Black, a network of 10 Black news publishers, to…
Black voices, Black bodies: Life in the age of Ozempic
STAT teamed up with Word In Black, a network of 10 Black news publishers, to…
Opinion: The uphill battle to provide noninvasive treatment for fibroids
If an effective treatment is available for one common disease in men, and that same…
Opinion: Saving rural psychiatry services will require higher Medicaid payments
If there were ever to be an empty bed in the stress unit my psychiatrist…
Heat waves associated with increased risk of preterm birth in the U.S.
Heat waves are becoming more frequent and more intense, posing more of a health risk…
ASCO 2024: the latest in cancer research
The ASCO annual meeting is widely considered one of the largest and most prestigious cancer…
STAT+: Dark money group runs ads on China biotech bill
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Pharmalittle: We’re reading about the Cencora data breach, a failed pandemic treaty, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
Biotech’s most interesting fundraisings from the last week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Airway disease drug from Insmed succeeds in one of the year’s most anticipated trials
An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway…
STAT+: Merus drug, with immunotherapy, boosts tumor response in patients with head and neck cancer
Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor…